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interventional benefit was indicated for other outcomes, al-
though it was not statistically significant based only on the 
two RCTs. Results from the analysis of outcomes from NRSs 
are consistent with those from RCTs and demonstrated a 
beneficial effect, which could be considered as supporting 
evidence.  Conclusions: Lung lavage with diluted surfactant 
appeared to improve the clinical outcome in infants with 
MAS. Given that less than 100 infants were included in the 
two RCTs, the findings of this study may still be regarded as 
insufficient evidence. Further research will be needed to 
confirm the benefit as well as to refine the lavage technique. 
 Copyright © 2011 S. Karger AG, Basel 
 Background 
 Meconium aspiration syndrome (MAS) is an impor-
tant cause of respiratory distress in neonates, sometimes 
leading to respiratory failure and even death  [1, 2] . Ther-
apy for MAS is mainly supportive, but use of innovative 
treatments such as high-frequency ventilation or inhaled 
nitric oxide has increased and seems to be of benefit to 
patients who are refractory to conventional mechanical 
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 Abstract 
 Background: Lung lavage with diluted surfactant has 
emerged as an innovative treatment for meconium aspira-
tion syndrome (MAS). However, the treatment effect has not 
yet been fully established.  Objective: To investigate the ef-
fects of surfactant lavage therapy for MAS by a systematic 
meta-analysis.  Methods: Relevant studies were identified by 
database searches in MEDLINE (from 1950), EMBASE (from 
1980), and CENTRAL, up to June 2010, and by additional hand 
searches. Meta-analyses were separately conducted for ran-
domized controlled trials (RCTs) and non-randomized con-
trolled studies (NRSs). Risk of bias was assessed and clinical 
as well as statistical heterogeneities were also investigated 
in explaining the potential bias.  Results: Two RCTs (87 pa-
tients) and eight NRSs (178 patients) were identified. From 
the results of the meta-analysis of RCTs, surfactant lavage 
significantly decreased death or the need for extracorpo-
real membrane oxygenation (RR 0.34, 95% CI 0.11, 0.99). An 
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ventilation  [2, 3] . However, these therapies are not rou-
tinely available.
 The pathophysiology of MAS is characterized by air-
way obstruction, chemical pneumonitis by aspirated me-
conium, and pulmonary hypertension induced by in ute-
ro hypoxia  [4, 5] . Meconium damages the alveolar epithe-
lium and inhibits pulmonary surfactant function; this 
inhibitory action is concentration-dependent  [6, 7] . Based 
on these rationales, surfactant therapy is thought to have 
a direct influence on the pathophysiology of MAS.
 Treatment options with surfactant for MAS include 
bolus surfactant administration and lung lavage with di-
luted surfactant. Bolus surfactant therapy has been found 
to improve oxygenation  [8, 9] . A recent systematic review 
based on four randomized controlled trials (RCTs) for 
bolus surfactant therapy in MAS suggested that surfac-
tant therapy decreases progressive respiratory failure re-
quiring extracorporeal membrane oxygenation (ECMO), 
though the effect on mortality or pulmonary morbidity 
was not shown  [10] .
 Lung lavage with diluted surfactant has been proposed 
as an alternative method of surfactant use for MAS, 
which could, theoretically, alter the natural course of 
MAS by enhancing the removal of meconium from the 
airways and augment surfactant function  [11] . Several in-
vestigators have reported that diluted surfactant lavage 
improved oxygenation in infants with MAS and surfac-
tant lavage was done safely in most of the studies  [12–16] . 
A review of surfactant therapy in MAS suggested a reduc-
tion in ventilator days and a lower incidence of pneumo-
thorax for surfactant lavage therapy; however, clinical 
outcomes of interest other than those were not compre-
hensively evaluated  [17] .
 In this study, we conducted a meta-analysis by system-
atically reviewing the most up-to-date available evidence 
in the current literature to assess the effectiveness of sur-
factant lavage therapy for infants with MAS.
 Methods 
 Study Inclusion, Data Extraction, and Bias Assessment 
 We evaluated RCTs and non-randomized controlled studies 
(NRSs) meeting the following inclusion criteria: (1) the patients 
were infants with MAS, and (2) lung lavage with diluted surfac-
tant was compared to a non-surfactant control. Case reports, let-
ters, commentaries and narrative reviews were excluded.
 Three electronic databases, MEDLINE (from 1950), EMBASE 
(from 1980), and CENTRAL (Cochrane Central Register of Con-
trolled Trials) were searched up to June 2010. We also screened 
abstracts published from 2000 to June 2010 in  Pediatric Research 
or from meetings of Pediatric Academic Societies. Search strate-
gies were constructed using the terms ‘meconium’, ‘meconium 
aspiration syndrome’, ‘surfactant’, and ‘lavage’. Some local data-
bases and bibliographies of relevant articles were also searched. 
No language restrictions were applied.
 A standardized form was used for data extraction and the fol-
lowing outcomes were abstracted: mortality, need for ECMO, air 
leaks (pneumothorax, pulmonary interstitial emphysema, pneu-
momediastinum, and pneumopericardium), pneumothorax, du-
ration of mechanical ventilation, duration of supplemental oxy-
gen, and duration of hospital stay. The composite outcome of 
death or need for ECMO was considered the primary outcome.
 The quality of eligible RCTs was assessed using Cochrane Col-
laboration’s tool for assessing the risk of bias for RCTs  [18] . For the 
NRSs, the methodological quality was assessed regarding the se-
lection of the intervention group, the comparison with contem-
porary groups, the baseline comparability of groups, and the 
blinding of the investigators and outcome assessments  [19] . The 
decision on eligibility, data extraction and the risk of bias assess-
ment was done by at least two reviewers independently and any 
differences in assessment were resolved by discussions between 
the authors.
 Statistical Analysis 
 A meta-analysis was done with the relative risk calculated for 
dichotomous outcomes. We primarily used a fixed-effects model 
with weighting of each individual study parameter according to 
the reciprocal of its variance since there was no statistical hetero-
geneity present. The random-effects model was additionally used 
to check how the results might differ with a change in the model 
assumption. The test for heterogeneity was done based on   2 sta-
tistics and the statistical heterogeneity was evaluated at a 10% 
significance level. I 2 values were also calculated to assess the ap-
propriateness of combining study results. Continuous outcomes 
were descriptively presented in a table without statistical pooling 
due to the skewness of the data. All analyses were separately con-
ducted according to the study design (RCT vs. NRS) for each 
outcome. An additional subgroup analysis was also done to iden-
tify the effect of intervention on mortality according to ECMO 
availability. Publication bias was assessed by funnel plot asym-
metry and Egger’s test  [20] . All analyses were done using the Sta-
ta Statistical Package Version 11 (Stata Corp., College Station, 
Tex., USA).
 Results 
 Study Description 
 Out of 474 articles identified by the initial search strat-
egies, ten studies were included in the analyses: two RCTs 
 [13, 21] and eight NRSs  [12, 14–16, 22–25] (Appendix 1). 
The characteristics of the studies included are presented 
in  table 1 . One study performed saline lavage for some of 
the patients in the control group  [22] . In all the other 
studies, respiratory management for the control group 
did not differ from that for the intervention group except 
for the performance of surfactant lavage. Surfactant bolus 
therapy was given when necessary, irrespective of the 
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treatment group, in both the RCTs and two NRSs  [16, 25] . 
The studies included were observed to be clinically het-
erogeneous in the severity of the disease, method of sur-
factant lavage, initial intervention time, and combined 
treatment modalities.
 Risk of Bias Assessment 
 Of the two RCTs, the patient allocation procedure was 
adequate in one study  [21] . In the other study, the alloca-
tion procedure was unclear and it was also thought that 
performance bias may have existed because the number 
of patients receiving rescue therapy was more than the 
number of patients with treatment failures, though res-
cue therapies were not allowed unless patients met treat-
ment failure  [13] . The study was conducted without a for-
mal sample size calculation but based on an estimate for 
assessing the safety and potential of efficacy in a rather 
exploratory fashion.
 For the three NRSs with concurrent control  [14, 16, 
22] , the choice of combined treatments, such as high-fre-
quency ventilation or inhaled nitric oxide, could have 
been biased by the knowledge of the allocation of inter-
vention. With five NRSs having historical control  [12, 15, 
23–25] , advances in respiratory support in neonate in-
tensive care are thought to be components able to cause 
bias. For baseline comparability, Kowalska et al.  [24] re-
ported that the proportion of infants with an Apgar score 
of 0–3 points in the first minute after delivery in the con-
Table 1.  Characteristics of the studies included
Study (first 
author)
Study 
design
Study population
(treatment year, 
number of subjects)
Baseline OI
(i/c)
Mean timing
of lavage
(h after birth)
Total lavage 
volume
Aliquot 
volume
Lavage
fluid
concentration
ECMO
availability
Use of 
HFV
(i, c)
Use of 
iNO
(i, c)
Wiswell
2002 [13]
RCT (i) n = 15
(c) n = 7
average 12 14–15 48 ml/kg 8 ml/kg Lucinactant
2.5–10 mg/ml
yes yes yes
Dargaville
2011 [21] 
RCT (i) n = 30
(c) n = 35
average 25 14 30 ml/kg 15 ml/kg Beractant
5 mg/ml
available in 
some centers 
yes yes
Dargaville
2007 [16]
NRS (i) 1999–2002, n = 8
(c) 1997–2003, n = 34
concurrent control
40/34 29.5
(median 23)
9–30 ml/kg 3–15 ml/kg Beractant
5 mg/ml
yes yes
(100%)
yes
(88%,
71%)
Chang
2003 [14]
NRS (i) 2000–2002, n = 12
(c) 2000–2002, n = 10
concurrent control
32.5/31.4 4.2 or 5.2 6–7 ml/kg or 
12–14 ml/kg
2 ml Beractant
10 mg/ml
or 5 mg/ml
not
reported
yes
(100%)
yes
(42%,
90%)
Schlösser
2002 [22]
NRS (i) 1987–1998, n = 11
(c) 1987–1998, n = 7
concurrent control
22/15.8 not reported 20 ml 5 ml Beractant
5 mg/ml
yes yes
(18%,
14%)
yes 
(55%, 
71%)
Kawano
1999 [25]
NRS (i) 1992–1997, n = 17
(c) 1987–1992, n = 17
historical control
not reported 6.3 approx. 
7–10 ml/kg
approx. 
2–3 ml/kg
Lavage fluid
not specified
6 mg/ml
yes yes (i) yes
(since 
1993)
(c) no
Lee 
2008 [23]
NRS (i) 2006–2007, n = 7
(c) 2005–2006, n = 8
historical control
16.9/15.3 10.35 20 ml/kg 2.5 ml/kg Beractant
5.3 mg/ml
not
reported
not
reported
not
reported
Lam
1999 [12]
NRS (i) 1996–1997, n = 6
(c) 1994–1995, n = 6
historical control
18.4/20.9 3 15 ml/kg 2 ml Beractant
5 mg/ml
no not
reported
not
reported
Salvia-
Roiges
2004 [15]
NRS (i) 1997–2000, n = 7
(c) 1996–1997, n = 6
historical control
31.0/27.2 median 6 15 ml/kg 3.75 ml/kg Beractant
5 mg/ml
not
reported
no yes
Kowalska
2002 [24]
NRS (i) 1998–2000, n = 11
(c) 1995–1997, n = 11
historical control
19.0/22.4 <6 15 ml/kg not reported Beractant
5 mg/ml
not
reported
not
reported
not
reported
i = Intervention group; c = control group; OI = oxygen index; ECMO = extracorporeal membrane oxygenation;  HFV = high-frequency ventilation; 
iNO = inhaled nitric oxide; RCT = randomized controlled study; NRS = non-randomized study.
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trol group was greater than in the intervention group. In 
the studies by Schlösser et al.  [22] and Dargaville et al. 
 [16] , the initial oxygen index of the intervention group 
was higher on average than that of the control group. In 
the other studies, the difference in the baseline charac-
teristics between the groups was not considered a con-
cern.
 Investigators were not blinded in any of the RCTs or 
NRSs. Though all outcomes are considered objective 
measures, some outcomes, such as duration of mechani-
cal ventilation or oxygen therapy, can also possibly be af-
fected by the clinicians’ blinding because those are deter-
mined under their direct control. Results of the assess-
ments of both RCTs and NRSs are summarized in  table 2 .
Table 2. R isk of bias assessment of the studies included
Study design/ID How allocation occurred Comparabil-
ity between 
groups
Blinding 
of inter-
vention
Free of 
other 
bias
RCT
Wiswell, 2002 no description for process of randomization and allocation concealment yes no no
Dargaville, 2011 adequate process of randomization and allocation concealment yes no yes
NRS
Dargaville, 2007 concurrent controls by clinician’s decision no no unclear
Chang, 2003 concurrent controls upon parent’s consent yes no unclear
Schlösser, 2002 concurrent controls; no description of method of allocation no no unclear
Kawano, 1999 historical controls yes no unclear
Lee, 2008 historical controls yes no unclear
Lam, 1999 historical controls yes no unclear
Salvia-Roiges, 2004 historical controls yes no unclear
Kowalska, 2002 historical controls no no unclear
Table 3.  Summary of meta-analyses
Outcome RCT NRS
studies
n
patients 
n (i/c)
RR (95% CI) I2 (p value) studies
n
patients
n (i/c)
RR (95% CI)   I2  (p value)
Death or need
for ECMO
2 45/42 fixed
random
0.34 (0.11–0.99)
0.34 (0.12–1.00)
0% (0.794) 6 64/57 fixed
random
0.35 (0.13–0.94)
0.33 (0.11–1.00)
0% (0.698)
Mortality (overall) 1 30/35 fixed
random
0.44 (0.13–1.50) NA 6 55/74 fixed
random
0.41 (0.13–1.26)
0.43 (0.13–1.48)
0% (0.820)
EC MO available 1 11/14 fixed
random
1.27 (0.21–7.65) NA 2 19/41 fixed
random 
1.64 (0.19–14.58)
1.61 (0.18–14.40)
0% (0.845)
ECMO 
unavailable
1 19/21 fixed
random
0.18 (0.02–1.39) NA 4 36/33 fixed
random
0.23 (0.05–1.01)
0.24 (0.05–1.04)
0% (0.988)
Need for ECMO 2 26/21 fixed
random 
0.27 (0.04–1.86)
0.30 (0.04–2.08)
0% (0.617) 3 36/55 fixed
random 
0.41 (0.11–1.48)
0.43 (0.10–1.86)
0% (0.371)
Air leak – – – – 6 56/82 fixed
random 
0.52 (0.28–0.96)
0.61 (0.33–1.14)
0% (0.698)
Pneumothorax 2 45/42 fixed
random
0.39 (0.08–1.95)
0.42 (0.07–2.37)
0% (0.327) 5 58/51 fixed
random 
0.45 (0.23–0.89)
0.52 (0.23–1.20)
15.4% (0.316)
RCT = Randomized controlled trial; NRS = non-randomized controlled study; n = number; i = intervention group; c = control group; RR = risk ratio; 
CI = confidence interval; NA = not applicable.
Results of statistical significance or of marginally statistical significance at the 5% level are indicated in boldface.
Studies that reported the outcome but in which no event occurred in any of the treatment groups, and therefore are of no contribution to the analysis, 
were excluded from counts of the number of studies and patients.
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Death or need for ECMO RR (95% CI) Events,
intervention
Events,
control
Weight 
%
Randomized controlled trials
Wiswell, 2002 [13] 0.47 (0.03, 6.43) 1/15 1/7 8.68
Dargaville, 2011 [21] 0.32 (0.10, 1.04) 3/30 11/35 42.88
Total 0.34 (0.12, 1.00) 4/45 12/42 51.56
Heterogeneity (I2 = 0.0%, p = 0.794)
Non-randomized studies
Chang, 2003 [14] 0.17 (0.01, 3.16) 0/12 2/10 6.96
Kawano, 1999 [25] 0.20 (0.03, 1.54) 1/17 5/17 14.35
Lam, 1999 [12] 0.20 (0.01, 3.46) 0/6 2/6 7.35
Salvia-Roiges, 2004 [15] 0.29 (0.01, 6.07) 0/7 1/6 6.48
Kowalska, 2002 [24] 0.33 (0.02, 7.39) 0/11 1/11 6.21
Schlösser, 2002 [22] 3.33 (0.18, 60.68) 2/11 0/7 7.09
Lee, 2008 [23] excluded 0/7 0/8 0.00
Total 0.33 (0.11, 1.00) 3/71 11/65 48.44
Heterogeneity (I2 = 0.0%, p = 0.698)
Overall total 0.34 (0.15, 0.73) 7/116 23/107 100.00
Heterogeneity (I2 = 0.0%, p = 0.878)
Mortality
Randomized controlled trials
Dargaville, 2011 [21] 0.44 (0.13, 1.50) 3/30 8/35 49.82
Wiswell, 2002 [13] excluded 0/15 0/7 0.00
Total 0.44 (0.13, 1.50) 3/45 8/42 49.82
Heterogeneity (not applicable)
Non-randomized studies
Dargaville, 2007 [16] 1.30 (0.06, 29.23) 0/8 1/34 7.82
Chang, 2003 [14] 0.17 (0.01, 3.16) 0/12 2/10 8.85
Lam, 1999 [12] 0.20 (0.01, 3.46) 0/6 2/6 9.34
Salvia-Roiges, 2004 [15] 0.29 (0.01, 6.07) 0/7 1/6 8.23
Kowalska, 2002 [14] 0.33 (0.02, 7.39) 0/11 1/11 7.90
Schlösser, 2002 [22] 2.00 (0.09, 43.22) 1/11 0/7 8.03
Kawano, 1999 [25] excluded 0/17 0/17 0.00
Lee, 2008 [23] excluded 0/7 0/8 0.00
Total 0.43 (0.13, 1.48) 1/79 7/99 50.18
Heterogeneity (I2 = 0.0%, p = 0.820)
Overall total 0.44 (0.18, 1.04) 4/124 15/141 100.00
Heterogeneity (I2 = 0.0%, p = 0.900)
Need for ECMO
Randomized controlled trials
Wiswell, 2002 [13] 0.47 (0.03, 6.43) 1/15 1/7 19.87
Dargaville, 2011 [21] 0.18 (0.01, 3.13) 0/11 3/14 16.66
Total 0.30 (0.04, 2.08) 1/26 4/21 36.53
Heterogeneity (I2 = 0.0%, p = 0.617)
Non-randomized studies
Dargaville, 2007 [16] 0.78 (0.04, 14.81) 0/8 2/34 15.74
Kawano, 1999 [15] 0.16 (0.02, 1.25) 1/17 5/14 33.26
Schlösser, 2002 [22] 2.00 (0.09, 43.22) 1/11 0/7 14.47
Total 0.43 (0.10, 1.86) 2/36 7/55 63.47
Heterogeneity (I2 = 0.0%, p = 0.371)
Overall total 0.38 (0.12, 1.21) 3/62 11/76 100.00
Heterogeneity (I2 = 0.0%, p = 0.680)
 Fig. 1. Forest plot of main outcomes: death or need for ECMO, mortality, need for ECMO. CI = Confidence interval; RR = risk ratio. 
10010.01
Favors intervention Favors control Note: weights are from random-effects analysis
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 Results of Meta-Analyses 
 Surfactant lavage significantly decreased death or the 
need for ECMO in both RCTs (RR 0.34, 95% CI 0.11, 0.99) 
and NRSs (RR 0.35, 95% CI 0.13, 0.94) ( fig. 1 ;  table 3 ). All 
studies except one by Schlösser et al.  [22] , in which more 
severe patients were involved in the treatment group at 
the baseline, consistently showed intervention-favorable 
results.
 All studies reported on mortality, but one RCT  [13] 
and two NRSs  [23, 25] found that no actual event oc-
curred. Mortality risk favored the intervention group in 
all studies in the analysis but two NRSs  [16, 22] ( fig. 1 ). In 
those two studies, the actual patients involved had a high-
er initial oxygen index in the intervention group at base-
line. If adjusting for the baseline condition, the treatment 
difference could be shifted towards a more consistent di-
rection of beneficial effect as with other studies’ results.
 The mortality was reported separately for ECMO-
available centers and ECMO-unavailable centers in the 
RCT  [21] . Out of six NRSs included in the analysis of 
mortality, three NRSs did not specifically mention the 
availability of ECMO during the study  [14, 15, 24] ; how-
ever, we determined from the circumstances that ECMO 
was not an available option for those studies. A subgroup 
analysis showed that the relative risk of mortality was 
fairly lower in the settings where ECMO was unavailable. 
The analyses of need for ECMO showed similar results of 
an interventional benefit both in the RCTs and the NRSs, 
although it was not statistically significant in either meta-
analysis.
 Only the NRSs reported on air leaks  [12, 15, 16, 23–25] , 
and the overall treatment effect was significant without a 
statistical heterogeneity. Both RCTs and five of the NRSs 
 [14, 15, 22, 24, 25] reported on pneumothorax. The treat-
ment difference did not reach a statistical significance in 
the RCTs. All the NRSs also suggested a reduced number 
of pneumothorax events in the intervention group and 
the combined effect was statistically significant. Howev-
er, in those NRSs, whether the event occurred before or 
after the intervention was given was not clearly described.
 No statistical heterogeneity was present in any of the 
meta-analyses. The spread of results in individual studies 
for the primary outcome and other outcomes is shown in 
 figure 1 . The combined result for each outcome using the 
random-effects model was also presented side by side 
with the result by the fixed-effects model in  table 3 . Both 
results were very similar in the two models on the whole, 
although there was a slight change from the statistical 
significance to the marginal borderline significance in 
the primary outcome, and the results on air leaks and 
pneumothorax from the NRSs lost statistical signifi-
cance. Funnel plot assessment did not reveal an indica-
tion for publication bias (Appendix 2). The significant 
asymmetry was not observed by Egger’s test (p = 0.686).
 Treatment Effects on Continuous Outcomes 
 Studies that reported on duration of mechanical ven-
tilation, duration of supplemental oxygen, and duration 
of hospital stay are summarized in  table 4 . Most of the 
studies, except for the two NRSs  [15, 16, 24] , showed a 
shorter duration for mechanical ventilation in the inter-
vention group. In the two RCTs, no treatment effect on 
the duration of supplemental oxygen was observed, while 
in the NRSs significant heterogeneity was present. Some 
Table 4.  Results of continuous outcomes
Study 
design
Study (first author) Number of 
patients (i/c)
Duration of mechanical ventilation Duration of supplemental oxygen D uration of hospital stay
intervention control intervention control interventi on control
RCT Wiswell, 2002 [13] 7/15 4.6 (1.1–22.3) 7.6 (1.1–28) 13.589.3 12.1810.7 12.788.7 13.1810.3 
Dargaville, 2011 [21] 30/35 5.5 (3.4–12) 6.0 (4.3–10) 14 (6.7–21) 14 (11–18) 16 (9.7–23) 18 (10–24)
NRS Dargaville, 2007 [16] 8/34 5.7 (–) 4.9 (–) – – – –
Chang, 2003 [14] 12/10 10.084.9 10.487.8 13.285.4 15.3812 17.686.1 19.589.7
Schlösser, 2002 [22] 11/7 5.987.3 7.382.4 8.687.0 7.382.8 – –
Kawano, 1999 [25] 17/17 13.8811.6 17.689.3 13.585.9 25.4815.4 31.8815.1 45.6814.4
Lee, 2008 [23] 7/8 1.780.1 2.880.4 2.280.6 3.480.3 9.082.3 12.684.1
Lam, 1999 [12] 6/6 2.382.1 5.482.5 4.180.5 20.188.1 – –
Salvia-Roiges, 2004 [15] 7/6 7.0 (5–10) 7.0 (4–8) 8.0 (6–12) 10.0 (7–13) 22.0 (14–29) 19.0 (13–28)
Kowalska, 2002 [24] 11/11 5.684.1 5.984.8 – – 20.588.8 22.4811.3
i = Intervention group; c = control group; RCT = randomized controlled study; NRS = non-randomized study.
All variables expressed by mean 8 SD or median (interquartile range).
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NRSs  [12, 25] showed more than a 10-day decrease in du-
ration of supplemental oxygen in the intervention group 
compared to the control group, whereas the other studies 
showed similar results with around 2 days of difference 
between the groups. Despite the observed variability of 
the results, most of the studies both in the RCTs and 
NRSs showed a shorter length of stay in the intervention 
group except one NRS.
 Discussion 
 Surfactant lavage showed a statistically significant 
beneficial effect on the primary outcome of death or need 
for ECMO in the meta-analysis of the two RCTs. A result 
of the subgroup analysis done to identify the effect of in-
tervention on mortality according to ECMO availability 
suggested that a composite evaluation of mortality and 
the need for ECMO, rather than mortality only, should be 
considered, since the mortality can be underestimated 
where ECMO was available. Although other outcomes, 
including mortality and a need for ECMO, did not dem-
onstrate a statistical significance based on those RCTs, a 
clear trend towards the beneficial effect in most of the 
outcomes was observed. Considering that there were only 
two randomized controlled studies available and that the 
number of patients included in those two RCTs combined 
was less than 100, this may be regarded as insufficient 
evidence, but yet indicative of a beneficial effect.
 As there were not enough RCTs available in the cur-
rent literature, we also investigated the results from non-
randomized comparative studies using a systematic ap-
proach to consider them as a supporting source of evi-
dence. The strength of the evidence to support the effect 
of surfactant lavage would have to be considered only as 
supporting evidence by taking into account the fact that 
there was a higher risk of bias in the NRSs. Some NRSs 
used a historical control, which can cause the later group, 
the intervention group, favorable results, as survival of 
infants with MAS has improved over time  [2] . On the 
other hand, the allocation methods in the NRSs with a 
concurrent control seemed to be prone to a selection bias. 
Nonetheless, comparing the results found from the RCTs, 
we have confirmed that the direction and the magnitude 
of the treatment effect were observed to be highly consis-
tent, which suggested that the evidence from the selected 
NRSs could supplement the current lack of RCTs. In the 
NRSs, the results of the meta-analysis suggested that sur-
factant lavage had a significant effect on air leaks, pneu-
mothorax, and death or the need for ECMO.
 The timing of the lavage may contribute to the results 
as discussed in some studies  [21, 26] . Early intervention 
is possibly more effective. Physiological changes started 
acutely within 1 h after the instillation of meconium and 
peak lung injury by meconium was observed between 12 
and 24 h in animal models  [5, 27] . The timing of the sur-
factant lavage in the studies that were included ranged on 
average from 3 to 30 h after birth and the postnatal age at 
the time of intervention in the RCTs tended to be late 
compared to that in the NRSs. The delay in administering 
the treatment in the RCTs may be due to the randomiza-
tion procedure in that the time for confirmation of inclu-
sion, acquisition of parent’s consent, and randomization 
and allocation were all required which was also men-
tioned in one study  [21] .
 Of the two RCTs, the subjects of one study had milder 
MAS than those of the other study (average baseline oxy-
gen index of 12 vs. 25). Results from the study in milder 
patients showed a trend towards reduction in duration of 
mechanical ventilation by surfactant lavage, while none 
of the patients died in either treatment group. On the oth-
er hand, the other study that involved patients with more 
severe conditions did not suggest a notable difference in 
the duration of respiratory support, but the surfactant 
lavage appeared to affect mortality. This suggests that 
whether the patients have a greater benefit from the in-
tervention could depend on the disease severity. Some 
further analyses stratified by the timing of the lavage or 
baseline severity of MAS would have been helpful to eval-
uate how these factors affect the effect of intervention. 
However, it was not possible to do such analyses in the 
current framework without having access to the individ-
ual patient data of each study.
 Though many studies presented a positive effect for 
surfactant lavage, there are still some concerns about its 
safety, that is, whether infants with MAS can tolerate the 
procedure or not. A large volume of fluid instillation to 
a lung might be a burden on a newborn, especially in 
cases of severe MAS with pulmonary hypertension; lung 
lavage may exacerbate hypoxia and lead to mortality 
 [28, 29] . In some NRSs, transient hypoxemia, bradycar-
dia, or hypotension was reported, which usually recov-
ered spontaneously and sometimes needed supportive 
management  [12, 14–16, 23] . In one RCT, 1 patient with 
intractable pulmonary hypertension died 3 h after the 
lavage  [21] . The other RCTs described 3 patients who 
failed to complete lavage therapy, though investigators 
explained that it might be partially related with another 
concomitant morbidity, not with lavage therapy. Pa-
tients in the RCTs received relatively large volumes of 
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 Appendix 2 
 Funnel plot for evaluation of publication bias: the primary out-
come of death or need for ECMO. The fitted line corresponds to 
the regression test for funnel plot asymmetry proposed by Egger 
et al.  [20] . RR = Risk ratio; log RR = log of the risk ratio.
 
 Appendix 1 
 Flow of systematic selection of literature.
mains to be determined. Long-term benefits such as re-
duction in neurological sequelae should be further as-
sessed. Safety by disease severity should also be investi-
gated.
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lavage fluid compared to those of the NRSs, which could 
be one of the reasons for the more frequent and more 
serious events found in the RCTs. An observational 
study comparing a small (20 ml) and a large (40 ml) 
 volume of diluted surfactant lavage for MAS reported 
fewer adverse events for the small lavage volume  [30] . 
Using a large volume of lavage in severe MAS would re-
quire caution because its risk can outweigh the potential 
benefit.
 Further trials should be supplemented to refine the 
method of surfactant lavage. Trials that compare different 
combinations of volumes, concentrations, and methods of 
delivery would be appropriate. The efficacy of surfactant 
lavage compared to other approaches such as surfactant 
bolus or combined use of surfactant lavage with bolus re-
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